The COSMIC-021 study began in 2017 to analyze the effects of cabozantinib alone or in combination with atezolizumab in patients with advanced solid tumors. New results from the study’s expansion cohorts demonstrate the efficacy of the treatment combination in patients with advanced urothelial carcinoma (UC). The phase Ib study enrolled patients with inoperable locally advanced or metastatic UC into one of four cohorts: first-line cisplatin-eligible, first-line cisplatin-ineligible, previous platinum-containing chemotherapy, or previous immune checkpoint inhibitor (ICI)-treated. ...
Advanced Urothelial Carcinoma
Advertisement
Latest News
EV with erdafitinib is a feasible combination with the ability to provide promising antitumor activity in mUC.
The indication for SG as a treatment for patients with pretreated aUC will be officially withdrawn by Gilead.
PIVOT-10 expanded on PIVOT-02 by further investigating BEMPEG with nivolumab in cisplatin-ineligible patients.
At ESMO Congress 2024, Drs. Petros Grivas, Bernadett Szabados, and Karine Tawagi discuss ctDNA biomarkers.
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
Drs. Tawagi, Nizam encourage earlier monitoring and intervention to mitigate EV-induced neuropathy in certain patients.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Advertisement
Section Editor
Amanda Nizam, MDGenitourinary Medical Oncologist | Cleveland Clinic
Advertisement
Get the latest UC research straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.